MX369618B - Oligonucleotido inhibidor y uso del mismo. - Google Patents
Oligonucleotido inhibidor y uso del mismo.Info
- Publication number
- MX369618B MX369618B MX2015006703A MX2015006703A MX369618B MX 369618 B MX369618 B MX 369618B MX 2015006703 A MX2015006703 A MX 2015006703A MX 2015006703 A MX2015006703 A MX 2015006703A MX 369618 B MX369618 B MX 369618B
- Authority
- MX
- Mexico
- Prior art keywords
- odns
- inhibitory
- production
- agonists
- tlr9
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 229940046166 oligodeoxynucleotide Drugs 0.000 abstract 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 2
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 102000004889 Interleukin-6 Human genes 0.000 abstract 1
- 208000010718 Multiple Organ Failure Diseases 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000016396 cytokine production Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229940100601 interleukin-6 Drugs 0.000 abstract 1
- 108010088383 interleukin-6 receptor alpha Proteins 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 abstract 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 abstract 1
- 230000000770 proinflammatory effect Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2012/085547 WO2014082254A1 (en) | 2012-11-29 | 2012-11-29 | Inhibitory oligonucleotide and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015006703A MX2015006703A (es) | 2015-08-05 |
| MX369618B true MX369618B (es) | 2019-11-14 |
Family
ID=50827048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015006703A MX369618B (es) | 2012-11-29 | 2012-11-29 | Oligonucleotido inhibidor y uso del mismo. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9688992B2 (enExample) |
| JP (1) | JP6106280B2 (enExample) |
| KR (1) | KR102027023B1 (enExample) |
| AU (1) | AU2012395641B2 (enExample) |
| CA (1) | CA2891906A1 (enExample) |
| MX (1) | MX369618B (enExample) |
| PH (1) | PH12015501182B1 (enExample) |
| RU (2) | RU2015120365A (enExample) |
| SG (1) | SG11201504142WA (enExample) |
| WO (1) | WO2014082254A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014082254A1 (en) | 2012-11-29 | 2014-06-05 | Changchun Huapu Biotechnology Co., Ltd | Inhibitory oligonucleotide and use thereof |
| CN108431228A (zh) * | 2015-12-25 | 2018-08-21 | Sbi生物技术有限公司 | Tlr抑制性寡核苷酸及其用途 |
| US20190060286A1 (en) | 2016-02-29 | 2019-02-28 | University Of Florida Research Foundation, Incorpo | Chemotherapeutic Methods |
| EP3468605A4 (en) * | 2016-06-08 | 2020-01-08 | President and Fellows of Harvard College | MANIPULATED VIRAL VECTOR TO REDUCE INDUCTION OF IGNITION AND IMMUNE REACTIONS |
| JP7145853B2 (ja) * | 2016-11-09 | 2022-10-03 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 適応免疫調節のための方法および組成物 |
| AU2018364542A1 (en) | 2017-11-08 | 2020-04-16 | President And Fellows Of Harvard College | Compositions and methods for inhibiting viral vector-induced inflammatory responses |
| CN112798796B (zh) * | 2021-01-04 | 2024-02-02 | 东南大学 | 一种基于dna-paint的细胞膜上pd-l1蛋白检测方法及序列 |
| WO2022170396A1 (en) * | 2021-02-12 | 2022-08-18 | ViraLok Therapeutics Pty Ltd | Agents and methods for therapy and prophylaxis |
| CN116370494A (zh) * | 2022-11-14 | 2023-07-04 | 南昌大学 | CpG寡核苷酸对糖尿病神经病理痛疾病药物中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005072290A2 (en) | 2004-01-23 | 2005-08-11 | Joslin Diabetes Center | Methods of treating, reducing, or preventing autoimmune conditions |
| CN102851295B (zh) | 2006-08-28 | 2015-01-07 | 长春华普生物技术有限公司 | Toll 样受体调节性寡核苷酸及其用途 |
| US8030289B2 (en) | 2008-08-06 | 2011-10-04 | Changchun Huapu Biotechnology Co., Ltd. | Oligonucleotide and use thereof |
| CN101643496B (zh) | 2008-08-07 | 2015-09-09 | 长春华普生物技术有限公司 | 一种具有免疫抑制功能的寡核苷酸 |
| CA2762206C (en) | 2009-06-01 | 2017-06-27 | Idera Pharmaceuticals, Inc. | Potentiation of autoimmune and inflammatory disease treatments by immune regulatory oligonucleotide (iro) antagonists of tlr7 and tlr9 |
| US20130323242A1 (en) * | 2012-06-01 | 2013-12-05 | Ophthotech Corp. | Compositions comprising an anti-pdgf aptamer and a vegf antagonist |
| WO2014082254A1 (en) | 2012-11-29 | 2014-06-05 | Changchun Huapu Biotechnology Co., Ltd | Inhibitory oligonucleotide and use thereof |
-
2012
- 2012-11-29 WO PCT/CN2012/085547 patent/WO2014082254A1/en not_active Ceased
- 2012-11-29 US US14/442,799 patent/US9688992B2/en active Active
- 2012-11-29 RU RU2015120365A patent/RU2015120365A/ru not_active Application Discontinuation
- 2012-11-29 JP JP2015544288A patent/JP6106280B2/ja active Active
- 2012-11-29 SG SG11201504142WA patent/SG11201504142WA/en unknown
- 2012-11-29 AU AU2012395641A patent/AU2012395641B2/en not_active Ceased
- 2012-11-29 CA CA2891906A patent/CA2891906A1/en not_active Abandoned
- 2012-11-29 KR KR1020157014060A patent/KR102027023B1/ko not_active Expired - Fee Related
- 2012-11-29 MX MX2015006703A patent/MX369618B/es active IP Right Grant
-
2015
- 2015-05-27 PH PH12015501182A patent/PH12015501182B1/en unknown
-
2017
- 2017-05-25 US US15/605,488 patent/US10190122B2/en active Active
-
2018
- 2018-02-14 RU RU2018105485A patent/RU2018105485A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201504142WA (en) | 2015-06-29 |
| JP6106280B2 (ja) | 2017-03-29 |
| AU2012395641B2 (en) | 2019-10-03 |
| US20150299710A1 (en) | 2015-10-22 |
| RU2018105485A (ru) | 2019-08-14 |
| RU2015120365A (ru) | 2017-01-10 |
| JP2015536659A (ja) | 2015-12-24 |
| PH12015501182A1 (en) | 2015-08-17 |
| AU2012395641A1 (en) | 2015-05-28 |
| US9688992B2 (en) | 2017-06-27 |
| RU2018105485A3 (enExample) | 2019-08-14 |
| CA2891906A1 (en) | 2014-06-05 |
| MX2015006703A (es) | 2015-08-05 |
| PH12015501182B1 (en) | 2018-10-03 |
| US10190122B2 (en) | 2019-01-29 |
| KR20150089019A (ko) | 2015-08-04 |
| US20170335325A1 (en) | 2017-11-23 |
| KR102027023B1 (ko) | 2019-09-30 |
| WO2014082254A1 (en) | 2014-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015501182A1 (en) | Inhibitory oligonucleotide and use thereof | |
| DOP2018000010A (es) | Inhibidores peptídicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias | |
| ZA201904311B (en) | Cyclic dinucleotides as sting (stimulator of interferon genes) agonists | |
| IL275996A (en) | Treatment using cytokine-encoded RNA | |
| PH12016502099A1 (en) | 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors | |
| WO2016065349A8 (en) | Short non-coding protein regulatory rnas (sprrnas) and methods of use | |
| MX2017000331A (es) | Compuestos de aminopiridazinona como inhibidores de quinasas de proteina. | |
| IL254615B (en) | Modified pyrazole compounds useful in the treatment of diseases related to Iraq | |
| IL258471A (en) | 11,13-modified saxitoxins for the treatment of pain | |
| MX2023008693A (es) | Polinucleotidos moduladores. | |
| MX2022003323A (es) | Polinucleotidos dirigidos al sistema nervioso central. | |
| WO2015011694A3 (en) | Isotopologues of smad7 antisense oligonucleotides | |
| MX2021001186A (es) | Purinonas como inhibidores de proteasa especifica de ubiquitina 1. | |
| EP3995581A3 (en) | Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders | |
| MX386726B (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos. | |
| WO2016011306A3 (en) | Terminal modifications of polynucleotides | |
| WO2015085318A3 (en) | Targeted adaptive vaccines | |
| WO2016066744A3 (en) | Gip agonist compounds and methods | |
| WO2016040347A3 (en) | Microrna inhibitor system and methods of use thereof | |
| AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
| MX2018005872A (es) | Profarmacos de acido nucleico. | |
| WO2015169811A3 (en) | Anti-cxc chemokine receptor-2 binding molecules and uses thereof | |
| MX2017014752A (es) | Nuevos etinos de amidoheteroaril aroil hidrazida. | |
| MX2020006533A (es) | Inhibidores del receptor activado por proteasa-2. | |
| MX381990B (es) | Proceso para la preparación de sílices precipitadas, sílices precipitadas y sus usos, en particular para el refuerzo de polímeros. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |